论文部分内容阅读
AIM:This study was designed to evaluate the clinicalapplication of serum total sialic acid(TSA)in the diagnosisof cholangiocarcinoma(CCA).METHODS:Serum TSA was determined by periodate-resorcinol microassay in 69 patients with CCA,59 patientswith hepatocellular carcinoma(HCC),37 patients withcirrhosis,61 patients with chronic hepatitis and 50 healthyblood donors.RESULTS:The mean serum TSA concentration in CCA(2.41±0.70 mmol/L)was significantly higher than those ofHCC,cirrhosis,chronic hepatitis and healthy blood donors(1.41±0.37 mmol/L,1.13±0.31 mmol/L,1.16±0.26 mmol/L,and 1.10±0.14 mmol/L,respectively;P<0.001).Basedon ROC curve analysis,a cut-off point of 1.75 mmol/Ldiscriminated between CCA and HCC with a sensitivity,specificity and accuracy of 82.6 %,83.1%,and 82.8 %,respectively.CONCLUSION:Based on our results,serum TSA would be auseful marker for the differential diagnosis of CCA from HCC.
AIM: This study was designed to evaluate the clinicalapplication of serum total sialic acid (TSA) in the diagnosis of cholangiocarcinoma (CCA) .METHODS: Serum TSA was determined by periodate-resorcinol microassay in 69 patients with CCA, 59 patients with hepatocellular carcinoma (HCC) , 37 patients with chronic hepatitis and 50 healthy blood donors. RESULTS: The mean serum TSA concentration in CCA (2.41 ± 0.70 mmol / L) was significantly higher than those of HCC, cirrhosis, chronic hepatitis and healthy blood donors 0.13 mmol / L, 1.13 ± 0.31 mmol / L, 1.16 ± 0.26 mmol / L, and 1.10 ± 0.14 mmol / L, respectively; P <0.001) .Basedon ROC curve analysis CCA and HCC with a sensitivity, specificity and accuracy of 82.6%, 83.1%, and 82.8%, respectively.CONCLUSION: Based on our results, serum TSA would be a good marker for the differential diagnosis of CCA from HCC.